Archives

FORUS Therapeutics Inc (“FORUS”) Announces XPOVIO® (selinexor) Is Authorized for Sale by Health Canada

Jun 7, 2022

(OAKVILLE, Ontario) June 7, 2022 – FORUS Therapeutics Inc (“FORUS”), is pleased to announce that on May 31, 2022 XPOVIO® (selinexor) was authorized for sale by Health Canada in combination with bortezomib and dexamethasone for the treatment of adult...

Accessibility by WAH

FORUS Therapeutics Inc (“FORUS”) Announces XPOVIO® (selinexor) Is Authorized for Sale by Health Canada

Recent Posts

Recent Comments

Categories

Meta